Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis.
Hereditary amyloidosis
Immune cells
PADO concept
Small fibre neuropathy
siRNA
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
10
01
2023
accepted:
25
03
2023
revised:
21
03
2023
medline:
16
6
2023
pubmed:
5
4
2023
entrez:
4
4
2023
Statut:
ppublish
Résumé
Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a rare, but life-threatening protein misfolding disorder due to TTR gene mutations. Cardiomyopathy (ATTRv-CM) and polyneuropathy (ATTRv-PN) with early small nerve fibre involvement are the most common manifestations. Timely diagnosis and treatment initiation are key to limiting progression of disease. Corneal confocal microscopy (CCM) is a non-invasive method to quantify corneal small nerve fibres and immune cell infiltrates in vivo. This cross-sectional study investigated the utility of CCM in 20 patients with ATTRv amyloidosis (ATTRv-CM, n = 6; ATTRv-PN, n = 14) and presymptomatic carriers (n = 5) compared to 20 age- and sex-matched healthy controls. Corneal nerve fibre density, corneal nerve fibre length, corneal nerve branch density, and cell infiltrates were assessed. Corneal nerve fibre density and nerve fibre length were significantly lower in patients with ATTRv amyloidosis compared to healthy controls regardless of the clinical phenotype (ATTRv-CM, ATTRv-PN) and corneal nerve fibre density was significantly lower in presymptomatic carriers. Immune cell infiltrates were only evident in patients with ATTRv amyloidosis, which correlated with reduced corneal nerve fibre density. CCM identifies small nerve fibre damage in presymptomatic carriers and symptomatic patients with ATTRv amyloidosis and may serve as a predictive surrogate marker to identify individuals at risk of developing symptomatic amyloidosis. Furthermore, increased corneal cell infiltration suggests an immune-mediated mechanism in the pathogenesis of amyloid neuropathy.
Sections du résumé
BACKGROUND
BACKGROUND
Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a rare, but life-threatening protein misfolding disorder due to TTR gene mutations. Cardiomyopathy (ATTRv-CM) and polyneuropathy (ATTRv-PN) with early small nerve fibre involvement are the most common manifestations. Timely diagnosis and treatment initiation are key to limiting progression of disease. Corneal confocal microscopy (CCM) is a non-invasive method to quantify corneal small nerve fibres and immune cell infiltrates in vivo.
METHODS
METHODS
This cross-sectional study investigated the utility of CCM in 20 patients with ATTRv amyloidosis (ATTRv-CM, n = 6; ATTRv-PN, n = 14) and presymptomatic carriers (n = 5) compared to 20 age- and sex-matched healthy controls. Corneal nerve fibre density, corneal nerve fibre length, corneal nerve branch density, and cell infiltrates were assessed.
RESULTS
RESULTS
Corneal nerve fibre density and nerve fibre length were significantly lower in patients with ATTRv amyloidosis compared to healthy controls regardless of the clinical phenotype (ATTRv-CM, ATTRv-PN) and corneal nerve fibre density was significantly lower in presymptomatic carriers. Immune cell infiltrates were only evident in patients with ATTRv amyloidosis, which correlated with reduced corneal nerve fibre density.
CONCLUSIONS
CONCLUSIONS
CCM identifies small nerve fibre damage in presymptomatic carriers and symptomatic patients with ATTRv amyloidosis and may serve as a predictive surrogate marker to identify individuals at risk of developing symptomatic amyloidosis. Furthermore, increased corneal cell infiltration suggests an immune-mediated mechanism in the pathogenesis of amyloid neuropathy.
Identifiants
pubmed: 37014422
doi: 10.1007/s00415-023-11689-z
pii: 10.1007/s00415-023-11689-z
pmc: PMC10267010
doi:
Substances chimiques
Prealbumin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3483-3491Subventions
Organisme : Universitätsmedizin Essen Clinician Scientist Academy
ID : FU 356/12-2
Informations de copyright
© 2023. The Author(s).
Références
Nat Rev Neurol. 2019 Jul;15(7):387-404
pubmed: 31209302
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):
pubmed: 33597308
Prog Neurobiol. 2003 Dec;71(5):385-400
pubmed: 14757117
Neurology. 2002 Apr 9;58(7):1001-7
pubmed: 11940682
ESC Heart Fail. 2019 Dec;6(6):1128-1139
pubmed: 31553132
J Peripher Nerv Syst. 2016 Mar;21(1):5-9
pubmed: 26663427
J Neurol. 2018 Apr;265(4):976-983
pubmed: 29249054
Curr Eye Res. 2012 Nov;37(11):1012-8
pubmed: 22667765
Exp Eye Res. 2007 Apr;84(4):626-34
pubmed: 17254566
J Neurol. 2021 Jun;268(6):2109-2122
pubmed: 31907599
Neurology. 2015 Aug 25;85(8):675-82
pubmed: 26208957
Muscle Nerve. 2018 May;57(5):829-837
pubmed: 29211930
Eur J Neurol. 2021 Feb;28(2):630-638
pubmed: 33098366
Invest Ophthalmol Vis Sci. 2002 Mar;43(3):639-46
pubmed: 11867578
Arch Ophthalmol. 2007 Jul;125(7):908-15
pubmed: 17620569
Eur J Neurol. 2021 Mar;28(3):982-991
pubmed: 33369810
Orphanet J Rare Dis. 2013 Feb 20;8:31
pubmed: 23425518
Curr Eye Res. 2019 Aug;44(8):840-848
pubmed: 30909745
Semin Ophthalmol. 2012 Sep-Nov;27(5-6):138-48
pubmed: 23163268
Curr Opin Neurol. 2016 Feb;29 Suppl 1:S3-S13
pubmed: 26734951
Ann Clin Transl Neurol. 2015 Dec 28;3(2):88-100
pubmed: 26900579
Diabetes. 2014 Jul;63(7):2454-63
pubmed: 24574045
Orphanet J Rare Dis. 2021 Oct 3;16(1):411
pubmed: 34602081
BMC Neurol. 2019 Jun 28;19(1):146
pubmed: 31253122
Muscle Nerve. 2012 Nov;46(5):698-704
pubmed: 22996176
Lancet Neurol. 2011 Dec;10(12):1086-97
pubmed: 22094129
JAMA Ophthalmol. 2016 Sep 1;134(9):983-9
pubmed: 27367055
Eur J Neurol. 2020 Aug;27(8):1374-1381
pubmed: 32343462
Curr Opin Neurol. 2016 Feb;29 Suppl 1:S14-26
pubmed: 26734952
Heart Fail Rev. 2015 Mar;20(2):163-78
pubmed: 25408161
J Neuroinflammation. 2021 Apr 8;18(1):89
pubmed: 33832507
Graefes Arch Clin Exp Ophthalmol. 2005 Oct;243(10):1056-61
pubmed: 15856272
Curr Eye Res. 2008 Nov;33(11):940-5
pubmed: 19085376
Hum Mutat. 2014 Sep;35(9):E2403-12
pubmed: 25044787
J Peripher Nerv Syst. 2013 Mar;18(1):54-8
pubmed: 23521645
Neurology. 2018 Nov 20;91(21):e1999-e2009
pubmed: 30333157
Lancet Neurol. 2021 Jan;20(1):49-59
pubmed: 33212063
Curr Eye Res. 2022 Sep;47(9):1239-1245
pubmed: 35726825
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4459-67
pubmed: 17898266
J Leukoc Biol. 2003 Aug;74(2):172-8
pubmed: 12885933
J Neurol. 2021 Oct;268(10):3610-3625
pubmed: 32500375
Am J Ophthalmol. 2006 Nov;142(5):736-44
pubmed: 17056357
Amyloid. 2019;26(sup1):55-56
pubmed: 31343296
Biochem Biophys Res Commun. 2002 Jun 7;294(2):309-14
pubmed: 12051711
Clin Exp Optom. 2020 May;103(3):265-277
pubmed: 30834591
Amyloid. 2019 Mar;26(1):3-9
pubmed: 30793974
Eur Heart J. 2013 Feb;34(7):520-8
pubmed: 22745357
Sci Rep. 2021 Nov 24;11(1):22884
pubmed: 34819589
Acta Neuropathol. 1989;79(2):190-9
pubmed: 2512758
Neurology. 2016 Nov 22;87(21):2220-2229
pubmed: 27794111
Lancet. 2005 Oct 15-21;366(9494):1340-3
pubmed: 16226599
Diabetes. 2007 Aug;56(8):2148-54
pubmed: 17513704
Rev Neurol (Paris). 2016 Oct;172(10):645-652
pubmed: 27663057
Curr Opin Neurol. 2016 Feb;29 Suppl 1:S27-35
pubmed: 26734953